Palatin Technologies Inc.
4-C Cedar Brook Drive
Cedar Brook Corporate Center
Cranbury,
NJ 08512
United States - Map
Phone: 609-495-2200
Fax: 609-495-2201
Web Site: http://www.palatin.com
| Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The companys products in development include PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, including chronic heart failure and acute heart failure, as well as for the treatment of difficult-to-control hypertension, including dialysis patients with hypertension; Bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery and related indications; and PL-6983, a peptide melanocortin receptor agonists, for treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. John K. A. Prendergast Ph.D., 55
Co-Founder and Chairman |
$
60.00K | N/A | Dr. Carl Spana Ph.D., 46
Co-Founder, Chief Exec. Officer, Pres, Director of RhoMed Incorporated |
N/A
| N/A | Mr. Stephen T. Wills CPA, MST, 52
Chief Financial Officer, Principal Accounting Officer, Exec. VP of Operations, Treasurer and Sec. |
N/A
| N/A | Dr. Trevor Hallam Ph.D., 50
Exec. VP of R&D |
N/A
| N/A | Dr. Steven Fischkoff M.D.,
VP of Clinical Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.06% Nasdaq 
Profile
